[{"address1": "1210-1220 Washington St.", "address2": "Suite 210", "city": "Newton", "state": "MA", "zip": "02465", "country": "United States", "phone": "617 344 4190", "website": "https://acumenpharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel J. O'Connell M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1047590, "exercisedValue": 0, "unexercisedValue": 1034567}, {"maxAge": 1, "name": "Dr. James  Doherty Ph.D.", "age": 56, "title": "President & Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 730785, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Zuga", "title": "CFO & Chief Business Officer", "fiscalYear": 2024, "totalPay": 703157, "exercisedValue": 0, "unexercisedValue": 254161}, {"maxAge": 1, "name": "Dr. Grant A. Krafft Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "totalPay": 42000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caleb E. Finch Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William L. Klein Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Russell  Barton M.S.", "age": 66, "title": "Chief Operating Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 223680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Carranza", "title": "Vice President, Finance & Accounting and Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alex  Braun M.B.A.", "title": "VP & Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Derek M. Meisner Esq., J.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 752945, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.13, "dayLow": 2.0, "dayHigh": 2.17, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.13, "regularMarketDayLow": 2.0, "regularMarketDayHigh": 2.17, "payoutRatio": 0.0, "beta": 0.201, "forwardPE": -1.3267974, "volume": 192941, "regularMarketVolume": 192941, "averageVolume": 337951, "averageVolume10days": 506590, "averageDailyVolume10Day": 506590, "bid": 1.56, "ask": 2.59, "bidSize": 2, "askSize": 2, "marketCap": 122964048, "fiftyTwoWeekLow": 0.855, "fiftyTwoWeekHigh": 3.36, "allTimeHigh": 26.98, "allTimeLow": 0.855, "fiftyDayAverage": 1.5454, "twoHundredDayAverage": 1.34427, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 9696053, "profitMargins": 0.0, "floatShares": 35610511, "sharesOutstanding": 60573425, "sharesShort": 1311722, "sharesShortPriorMonth": 1405707, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.0217, "heldPercentInsiders": 0.070310004, "heldPercentInstitutions": 0.67819, "shortRatio": 4.06, "shortPercentOfFloat": 0.0292, "impliedSharesOutstanding": 60573425, "bookValue": 1.933, "priceToBook": 1.050181, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -136664992, "trailingEps": -2.27, "forwardEps": -1.53, "enterpriseToEbitda": -0.067, "52WeekChange": -0.24814814, "SandP52WeekChange": 0.13837254, "quoteType": "EQUITY", "currentPrice": 2.03, "targetHighPrice": 10.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.75, "targetMedianPrice": 6.5, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 143368992, "totalCashPerShare": 2.367, "ebitda": -143920992, "totalDebt": 30101000, "quickRatio": 5.789, "currentRatio": 5.969, "debtToEquity": 25.71, "returnOnAssets": -0.39056998, "returnOnEquity": -0.7571, "grossProfits": -124207000, "freeCashflow": -71940872, "operatingCashflow": -117764000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ABOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Acumen Pharmaceuticals, Inc.", "longName": "Acumen Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1625146200000, "postMarketChangePercent": 2.95566, "postMarketPrice": 2.09, "postMarketChange": 0.0599999, "regularMarketChange": -0.1, "regularMarketDayRange": "2.0 - 2.17", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 337951, "fiftyTwoWeekLowChange": 1.175, "fiftyTwoWeekLowChangePercent": 1.3742689, "fiftyTwoWeekRange": "0.855 - 3.36", "fiftyTwoWeekHighChange": -1.3299999, "fiftyTwoWeekHighChangePercent": -0.3958333, "fiftyTwoWeekChangePercent": -24.814814, "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1760743337, "regularMarketTime": 1760731201, "exchange": "NMS", "messageBoardId": "finmb_8539521", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": -4.69484, "regularMarketPrice": 2.03, "earningsTimestamp": 1754971200, "earningsTimestampStart": 1762864200, "earningsTimestampEnd": 1762864200, "earningsCallTimestampStart": 1755000000, "earningsCallTimestampEnd": 1755000000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.27, "epsForward": -1.53, "epsCurrentYear": -2.37852, "priceEpsCurrentYear": -0.8534719, "fiftyDayAverageChange": 0.48459995, "fiftyDayAverageChangePercent": 0.31357574, "twoHundredDayAverageChange": 0.68573, "twoHundredDayAverageChangePercent": 0.5101133, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-01", "averageAnalystRating": "1.0 - Strong Buy", "displayName": "Acumen Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-10-18"}]